Operating
Change in Accrued Liabilities
Gilead Sciences Change in Accrued Liabilities increased by 588.6% to $811.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 433.6%, from $152.00M to $811.00M. Over 2 years (FY 2021 to FY 2024), Change in Accrued Liabilities shows a downward trend with a -60.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2007
Last reportedQ3 2025
How to read this metric
An increase represents a source of cash through deferred payment, while a decrease represents a cash outflow as obligations are settled.
Detailed definition
Reflects the change in obligations for expenses incurred but not yet invoiced or paid, such as employee compensation, ta...
Peer comparison
Standard operating cash flow component found in almost all corporate financial statements.
Metric ID:
cf_change_in_accrued_liabilitiesHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | -$138.00M | $1.54B | -$1.66B | $362.00M | $164.00M | -$543.00M | $634.00M | $50.00M | $317.00M | -$175.00M | -$174.00M | $152.00M | $305.00M | -$244.00M | -$166.00M | $811.00M |
| QoQ Change | — | -652.0% | >999% | -207.6% | +121.8% | -54.7% | -431.1% | +216.8% | -92.1% | +534.0% | -155.2% | +0.6% | +187.4% | +100.7% | -180.0% | +32.0% | +588.6% |
| YoY Change | — | — | — | — | >999% | +218.8% | +67.2% | +75.1% | -69.5% | — | +67.8% | -127.4% | +204.0% | -3.8% | -39.4% | +4.6% | +433.6% |
Range-$1.66B – $1.54B
CAGR+138.7%
Avg YoY Growth+181.6%
Median YoY Growth+67.5%
Current Streak2 quarters growth
Change in Accrued Liabilities at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's change in accrued liabilities?
- Gilead Sciences (GILD) reported change in accrued liabilities of $811.00M in Q3 2025.
- How has Gilead Sciences's change in accrued liabilities changed year-over-year?
- Gilead Sciences's change in accrued liabilities increased by 433.6% year-over-year, from $152.00M to $811.00M.
- What is the long-term trend for Gilead Sciences's change in accrued liabilities?
- Over 2 years (2021 to 2024), Gilead Sciences's change in accrued liabilities has grown at a -60.4% compound annual growth rate (CAGR), from $689.00M to $108.00M.
- What does change in accrued liabilities mean?
- The net change in expenses that have been recognized but not yet paid.